Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,totalCurrentAssets,accountsPayable,otherAssets,propertyPlantEquipment,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,changeToNetincome,WC,language,region,quoteType,triggerable,quoteSourceName,currency,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,postMarketChangePercent,postMarketTime,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,priceHint,shortName,longName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,market,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,exchangeDataDelayedBy,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,GTBP,24185000.0,21127700,1640000,,-29677000,-169000,-29677000,27362000,0,-29002000,-29002000,,-696000,,,,0,0,29002000,0,-675000,,-29677000,-29677000,623287000.0,3626000.0,24185000.0,362000.0,27643000.0,21000.0,-625079000.0,25956000.0,27555000.0,3626000.0,25956000.0,27643000.0,2377000.0,,,219000,1205000,25942000,972000,24737000,22258000,-3684000,24802000,24017000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,8.69,0.0,-2.2497272,8.5048 - 9.02,8.89,0.0,0.0,13,11,finmb_265434,NasdaqCM,USD,356345,584314,6.1909995,2.4773908,2.499 - 19.733,-11.043,-0.559621,2.499,19.733,1503273600,1621281600,1628539200,1628884800,0.0,1630528662,-7.588,-1.08,-2.03,-4.280788,-14400000,1.179,10.2982855,-1.6082859,-0.15617026,11.156087,-2.4660873,2,"GT Biopharma, Inc.","GT Biopharma, Inc.",8.69,1630526403,-0.20000076,8.93,9.02,8.5048,255850,PREPRE,NCM,us_market,-0.22105308,183599712,-8.046295,7.3706527,15,America/New_York,EDT,False,False,0,1.57,,,19.73,2.5,10.3,11.16,356.35k,584.31k,21.13M,,11M,4.28%,19.53%,2.04M,3.62,14.33%,9.63%,1.4M,,,,,,0.00%,"Aug 20, 2017",,1:17,"Feb 10, 2021","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-155.24%,"-3,558.82%",,,,,,-56.27M,-7.59,,27.55M,1.3,31k,0.13,7.62,1.18,-10.72M,-3.17M,Value,90212,Healthcare,3,"GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Beverly Hills, California.",Beverly Hills,800 304 9888,CA,1609372800,United States,http://www.gtbiopharma.com,86400,9350 Wilshire Boulevard,Biotechnology,Suite 203
t-1,GTBP,-29267000.0,21127700,233000,,-14933000,-169000,-14933000,1958000,0,-2191000,-2191000,,-696000,,,,0,0,2191000,0,-12742000,,-14933000,-14933000,566309000.0,35094000.0,-29267000.0,383000.0,5661000.0,52000.0,-595628000.0,,5297000.0,35094000.0,,5661000.0,2243000.0,,,-2203000,6874000,6874000,3239000,24737000,4947000,-1927000,11653000,-29433000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,8.69,0.0,-2.2497272,8.5048 - 9.02,8.89,0.0,0.0,13,11,finmb_265434,NasdaqCM,USD,356345,584314,6.1909995,2.4773908,2.499 - 19.733,-11.043,-0.559621,2.499,19.733,1503273600,1621281600,1628539200,1628884800,0.0,1630528662,-7.588,-1.08,-2.03,-4.280788,-14400000,1.179,10.2982855,-1.6082859,-0.15617026,11.156087,-2.4660873,2,"GT Biopharma, Inc.","GT Biopharma, Inc.",8.69,1630526403,-0.20000076,8.93,9.02,8.5048,255850,PREPRE,NCM,us_market,-0.22105308,183599712,-8.046295,7.3706527,15,America/New_York,EDT,False,False,0,1.57,,,19.73,2.5,10.3,11.16,356.35k,584.31k,21.13M,,11M,4.28%,19.53%,2.04M,3.62,14.33%,9.63%,1.4M,,,,,,0.00%,"Aug 20, 2017",,1:17,"Feb 10, 2021","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-155.24%,"-3,558.82%",,,,,,-56.27M,-7.59,,27.55M,1.3,31k,0.13,7.62,1.18,-10.72M,-3.17M,Value,90212,Healthcare,3,"GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Beverly Hills, California.",Beverly Hills,800 304 9888,CA,1609372800,United States,http://www.gtbiopharma.com,86400,9350 Wilshire Boulevard,Biotechnology,Suite 203
t-2,GTBP,-29633000.0,21127700,-84000,,-2876000,-169000,-2876000,2029000,0,-1945000,-1945000,,-931000,,,,0,0,1945000,0,-931000,,-2876000,-2876000,550984000.0,30694000.0,-29633000.0,,917000.0,78000.0,-580695000.0,,350000.0,30694000.0,,833000.0,2171000.0,12000.0,72000.0,1104000,1200000,1200000,-123000,24737000,-501000,-1701000,195000,-29861000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,8.69,0.0,-2.2497272,8.5048 - 9.02,8.89,0.0,0.0,13,11,finmb_265434,NasdaqCM,USD,356345,584314,6.1909995,2.4773908,2.499 - 19.733,-11.043,-0.559621,2.499,19.733,1503273600,1621281600,1628539200,1628884800,0.0,1630528662,-7.588,-1.08,-2.03,-4.280788,-14400000,1.179,10.2982855,-1.6082859,-0.15617026,11.156087,-2.4660873,2,"GT Biopharma, Inc.","GT Biopharma, Inc.",8.69,1630526403,-0.20000076,8.93,9.02,8.5048,255850,PREPRE,NCM,us_market,-0.22105308,183599712,-8.046295,7.3706527,15,America/New_York,EDT,False,False,0,1.57,,,19.73,2.5,10.3,11.16,356.35k,584.31k,21.13M,,11M,4.28%,19.53%,2.04M,3.62,14.33%,9.63%,1.4M,,,,,,0.00%,"Aug 20, 2017",,1:17,"Feb 10, 2021","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-155.24%,"-3,558.82%",,,,,,-56.27M,-7.59,,27.55M,1.3,31k,0.13,7.62,1.18,-10.72M,-3.17M,Value,90212,Healthcare,3,"GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Beverly Hills, California.",Beverly Hills,800 304 9888,CA,1609372800,United States,http://www.gtbiopharma.com,86400,9350 Wilshire Boulevard,Biotechnology,Suite 203
t-3,GTBP,-27355000.0,21127700,12000,,-8779000,-169000,-8779000,1546000,0,-1558000,-1558000,,-4658000,,,,0,0,1558000,0,-7221000,,-8779000,-8779000,550389000.0,28562000.0,-27355000.0,,1063000.0,75000.0,-577819000.0,,851000.0,28562000.0,,971000.0,2001000.0,12000.0,80000.0,-1161000,4257000,4257000,63000,24737000,846000,-3411000,6465000,-27591000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,8.69,0.0,-2.2497272,8.5048 - 9.02,8.89,0.0,0.0,13,11,finmb_265434,NasdaqCM,USD,356345,584314,6.1909995,2.4773908,2.499 - 19.733,-11.043,-0.559621,2.499,19.733,1503273600,1621281600,1628539200,1628884800,0.0,1630528662,-7.588,-1.08,-2.03,-4.280788,-14400000,1.179,10.2982855,-1.6082859,-0.15617026,11.156087,-2.4660873,2,"GT Biopharma, Inc.","GT Biopharma, Inc.",8.69,1630526403,-0.20000076,8.93,9.02,8.5048,255850,PREPRE,NCM,us_market,-0.22105308,183599712,-8.046295,7.3706527,15,America/New_York,EDT,False,False,0,1.57,,,19.73,2.5,10.3,11.16,356.35k,584.31k,21.13M,,11M,4.28%,19.53%,2.04M,3.62,14.33%,9.63%,1.4M,,,,,,0.00%,"Aug 20, 2017",,1:17,"Feb 10, 2021","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-155.24%,"-3,558.82%",,,,,,-56.27M,-7.59,,27.55M,1.3,31k,0.13,7.62,1.18,-10.72M,-3.17M,Value,90212,Healthcare,3,"GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Beverly Hills, California.",Beverly Hills,800 304 9888,CA,1609372800,United States,http://www.gtbiopharma.com,86400,9350 Wilshire Boulevard,Biotechnology,Suite 203
